Mehmet Oz has committed to defending Medicare drug price negotiations in court if he is confirmed to lead CMS.

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

Greg Behar’s shakeup of Recipharm is paying off in his first year as CEO, as the company reported record-high revenues on ...

The UK government is planning to double the proportion of money drugmakers have to pay back on medicine sales to the National ...

HHS Secretary Robert F. Kennedy Jr. and his staff last Wednesday hosted a regenerative medicine roundtable primarily to ...

Sutro Biopharma is reducing its headcount by 50%, appointing a new CEO, shutting down its only factory, and shifting away ...

Pfizer's pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a ...

Celeste Warren said in a LinkedIn post that she is retiring from Merck on July 7. Warren joined Merck in 1997 and has been VP ...

Fauna Bio, a biotech that mines data on disease resistance from squirrels and other animals to create new drugs, is looking ...

MoonLake Immunotherapeutics expects mid-year readout for Phase 3 trials of sonelokimab in hidradenitis suppurativa; CEO da ...

Endo to merge with Mallinckrodt in $6.7B deal. Combined revenue expected at $3.6B by 2025. Deal to close in H2 2025.